Summary
The pharmacokinetics and dynamics of thed- andl-isomers of the beta-adrenergic blocking agent penbutolol were investigated in healthy human volunteers. In Study One, subjects received a single 40-mg oral dose ofl-penbutolol (the pharmacologically active stereoisomer), and matching placebo on two occasions. A mean peak serum penbutolol concentration of 268 ng/ml was reached at 0.9 h after dosing. Elimination half-life averaged 1.6 h, and total clearance 16.6 ml/min per kg body weight. Changes in blood pressure, ventricular rate, and rate of circumferential fiber shortening (Vcf) did not differ betweenl-penbutolol and placebo. In Study Two, subjects received 40 mgd-penbutolo,l-penbutolol, and placebo on three occasions. Total clearance ofd-penbutolol was higher than for thel-isomer (43.7 vs 15.9 ml/min/kg;P<0.01); this was reflected in correspondingly increased area under the serum concentration curve for conjugates of the oxidized metabolite 4-hydroxy penbutolol (2.25 vs 0.66 µg/ml×h;P<0.005). In contrast, direct conjugates ofl-penbutolol achieved higher serum concentrations than conjugates ofd-penbutolol. Alterations in blood pressure, ventricular rate, and Vcf ford-penbutolol,l-penbutolol, and placebo were quantitatively small. Thus the clearance of penbutolol after oral administration in humans is stereoselective, but the oxidative pathway is more stereosensitive than the parallel conjugative pathway. Penbutolol causes minimal alterations in parameters of cardiac function after single 40-mg doses in healthy humans.
Similar content being viewed by others
Abbreviations
- AUC:
-
Area under the curve
- d :
-
Dextro
- HPLC:
-
High pressure liquid chromatography
- l :
-
Levo
- Vcf:
-
Rate of circumferential fiber shortening
- t1/2:
-
Elimination half-life
References
Kaiser J (1980) Study on the action specificity of penbutolol and propranolol including their optical isomers. Arzneimittelforsch 30:427–432
Kaiser J, Härtfelder G, Lindner E, Schölkens B (1980) On the pharmacology of the β-receptor blocker penbutolol. Arzneimittelforsch 30:420–427
Kober G, Schulz W, Hermann H-J, Kaltenbach M (1984) Extent of beta-blocking action of S- and R-penbutolol during exercise testing. Z Kardiol 71:289–294
Tawara K, Kawashima K, Ishikawa H, Yamamoto K, Saito K, Ebihara A, Yoshida S (1981) Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients. Eur J Clin Pharmacol 19:197–203
Hartling OJ, Svendsen TL, Trap-Jensen J (1981) Systemic and forearm haemodynamic and metabolic effects of racemic propranolol ord-propranolol in healthy subjects. Clin Sci 60:675–679
Emrich HM, von Zerssen D, Moller H-J, Kissling W, Cording C, Schietsch HJ, Riedel E (1979) Action of propranolol in mania: comparison of effects of thed- and thel-stereoisomer. Pharmacopsychiatry 12:295–304
Rahn KH, Hawlina A, Kersting F, Planz G (1974) Studies on the antihypertensive action of the optical isomers of propranolol in man. Arch Pharmacol 286:319–323
Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HR (1983) Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther 34:732–737
Kawashima K, Ishikawa H (1980) Pharmacokinetics of propranolol isomers and their relationship with beta adrenoceptor blocking activity in rabbits administered withdl-propranolol. J Pharmacol Exp Ther 213:628–631
Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M (1984) Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability ofl- andd-verapamil examined with a stable isotope technique. Br J Clin Pharmacol 18:733–740
von Bahr C, Hermansson J, Tawara K (1982) Plasma levels of (+) and (−)-propranolol and 4-hydroxypropranolol after administration of racemic (±)-propranolol in man. Br J Clin Pharmacol 14:79–82
Silber B, Holford NHG, Riegelman S (1982) Stereoselective disposition and glucuronidation of propranolol in humans. J Pharm Sci 71:699–703
Walle UK, Walle T, Bai SA, Olanof LS (1983) Stereoselective binding of propranolol to human plasma, α1-acid glycoprotein, and albumin. Clin Pharmacol Ther 34:718–723
Schunack W (1981) Absolute Konfiguration und Wirkung der β-Rezeptorenblocker. Dtsch Apotheker Z 121: 2879–2881
Ochs HR, Grube E, Greenblatt DJ, Woo E, Bodem G (1980) Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J 99:468–475
Ochs HR, Grube E, Greenblatt DJ, Arendt R, Bodem G (1981) Pharmacokinetics and pharmacodynamics of intravenous digoxin and digitoxin. Klin Wochenschr 59:889–897
Ochs HR, Grube E, Greenblatt DJ, Knüchel M, Bodem G (1982) Kinetics and cardiac effects of propranolol in humans. Klin Wochenschr 60:521–525
Ochs HR, Grube E, Greenblatt DJ, Arendt R (1981) Intravenous quinidine in congestive cardiomyopathy. Eur J Clin Pharmacol 19:173–176
Ochs HR, Otten H, Greenblatt DJ, Dengler HJ (1982) Diazepam absorption: effects of age, sex, and Billroth gastrectomy. Dig Dis Sci 27:225–230
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–390
Francis RJ, East PB, Larman J (1982) Kinetics and metabolism of (+)-, (−)- and (±)-Bufuralol. Eur J Clin Pharmacol 23:529–533
Author information
Authors and Affiliations
Additional information
Supported in part by Grant Oc/10 6-4 from Deutsche Forschungsgemeinschaft, by Hoechst AG, Frankfurt, Federal Republic of Germany; and by Grant MH-34223 from the United States Public Health Service
Rights and permissions
About this article
Cite this article
Ochs, H.R., Hajdú, P. & Greenblatt, D.J. Pharmacokinetics and dynamics of penbutolol in humans: Evidence for pathway-specific stereoselective clearance. Klin Wochenschr 64, 636–641 (1986). https://doi.org/10.1007/BF01726915
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01726915